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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S201Background: Calcineurin inhibitors (CI) such as cyclosporine
A (CsA) and tacrolimus often cause renal dysfunction
resulting in an increase in serum creatinine (Cr), hyper-
kalemia, hypomagenesemia, and hyperuricemia. Electrolyte
and uric acid abnormalities are considered mainly due to
renal tubular impairment. However, the effects of CI on the
sodium regulation have yet to be fully evaluated. In the
present study, we have quantitatively evaluated the effects of
CI on urinary sodium excretion in patients receiving tar-
olimus or CsA in the early period after allogenetic hemato-
poietic stem cell transplantation (HSCT).
Patients and Methods: One hundred recipients of allogeneic
HSCT receiving CI (CsA, n¼50; tacrolimus, n¼50) with the
available weekly data for calculating fractional excretion of
sodium (FENa) for 4-week period after transplantation were
enrolled. No signiﬁcant differences were observed in patient
characteristics except for the type of donor between CsA and
tarolimus groups. FENa was calculated according to the
following formula: 100 x (Urinary sodium x Serum Cr)/
(Serum sodium x Urinary Cr).
Results: Both CsA and tarolimus groups showed increase in
FENa at 2nd to 4th weeks after transplantation as compared
with those at 1st week (0.960.44 for CsA; 0.920.49 for
tacrolimus). Among them, a signiﬁcant increase was only
observed at 3rd and 4th weeks in tacrolimus group, but not
in CsA group. In addition, FENawas signiﬁcantly higher at 4th
week in tacrolimus group as compared with CsA group
(1.601.12 vs. 1.130.80 :p<0.05).
Conclusion: These results suggest that urinary sodium
excretion increases under the administration of CI after
allogeneic HSCT probably through renal tubular impairment
and that there is a signiﬁcant difference in the renal tubular
toxicity between tacrolimus and CsA.305
Antibiotic Prophylaxis Therapy for Pediatric Patients
Undergoing Hematopoietic Stem Cell Transplant (HSCT):
A Tale of 2 Centers
Tal Schechter 1, Adam Gassas 1, Joshua Klein 1, John Doyle 2,
Amanda Berger 3, Muhammad Ali 1, Pengcheng Lu 3,
Jennifer Domm4, Joerg Krueger 1, R. Maarten Egeler 1,
Sarah Alexander 1, Haydar A. Frangoul 5. 1 Haematology/
Oncology, The Hospital for Sick Children, Toronto, ON, Canada;
2 Paediatric Hematology/Oncology, CancerCare Manitoba,
Winnipeg, MB, Canada; 3 Vanderbilt University, Nashville, TN;Figure 14Division of Hematology/Oncology, Vanderbilt University,
Nashville, TN; 5 Vanderbilt University Medical Center, Nashville,
TN
Introduction: Bacterial infections are a leading cause of
morbidity and treatment-related mortality in children
following hematopoietic stem cell transplant (HSCT). Meta-
analysis of studies of bacterial prophylaxis in adult oncology
patients with neutropenia showed a signiﬁcantly decreased
risk of death associated with prophylaxis regimens. How-
ever, the use of prophylaxis vs. empiric treatment is
controversial in the setting of HSCT and data in children is
limited. The concerns for using prophylaxis therapy are
development of antibiotic resistance and increased drug-
related toxicity. An empiric approach to antibiotic therapy
prompts the concern that therapy is delayed until an infec-
tion has already occurred. Our study aimed to compare the
bacteremia rates in two pediatric centers that use contrast-
ing approaches; empiric vs. prophylaxis.
Methods:Wecompared the incidenceof bacterial infections in
pediatric HSCT patients in two units; The Hospital for Sick
Children (SickKids) where an empiric antibiotic strategy is
utilized and Vanderbilt University Medical Center, where pro-
phylaxis antibiotic (Ceﬁpime) is givenwhen ANC<500/ul or on
the day of transplant, which ever is earlier. Baseline character-
isticswerecomparedbetween the2groupswith2sample tests,
where categorical variables and continuous variables were
evaluated using double-sided Fisher exact tests respectively.
Results: 224pediatricpatients fromSickKids and294pediatric
patients from Vanderbilt who underwent autologous and
allogeneic HSCTs between 2005-2010 were evaluated. Total
bacteremia rate (Gram positive and Gram negative) was
signiﬁcantly higher at SickKids (68/224) vs. Vanderbilt (49/
294), p<0.001). At SickKids,19% presented with Gram positive
infection as their ﬁrst infection at a mean of 8.9 d after trans-
plant and 11% with gram negative infection at a mean of 4.0
d after transplant.At Vanderbilt, 14% presented with gram
positive infectionatameanof9.5dafter transplant and2%with
gram negative infection at a mean of 5.2 d after transplant. No
treatment-relatedmortality in theﬁrst 100dayswasattributed
to bacterial infections in either center. Using a multivariable
model including: age, diagnosis (malignant vs. non-malignant)
and type of transplant ( allogeneic vs. autologous), only anti-
biotic prophylaxis approach resulted in a signiﬁcantly lower
gram negative bacteremia (p¼<0.001) and a trend toward
lower incidence of gram positive bacteremia (p¼0.052)..
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S202Conclusions: The use of antibiotic prophylaxis in pediatric
HSCT decreased the incidence of bacteremia during trans-
plant. The use of antibacterial prophylaxis in pediatric pa-
tients undergoing HSCT should be considered, and
prospective studies are needed to conﬁrm our results.306
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Background: Multiple studies of improved glycemic control
in critically ill patients have yielded contradictory results.
Few studies on inpatient hyperglycemia exist in the BMT
population. We undertook a quality improvement project to
improve blood glucose (BG) control with a goal of increasing
the proportion of time that patients on our BMTservice spent
within the range of 70-200 mg/dl.
Methods: With the Division of Endocrinology, an algorithm
for the initiation and modiﬁcation of ﬁnger sticks and anti-
hyperglycemic medications was created and implemented
on the Tufts Medical Center BMT service for admissions
between 4/1-6/30/13 that were predicted to be > 48 hours
in duration (intervention). Using the Remote Automated
Laboratory System (RALS), the percent of time in each BG
range (<70, 71-110, 111-140, 141-199, >200) was calculated
for the entire ﬂoor in the three months prior to imple-
mentation(baseline) and during the threemonths of the pilot
program. As the oncology service is included in thiscalculation and was not part of our intervention, admissions
were analyzed for comparison. With IRB approval, retro-
spective data of admissions >48 hours was collected to
evaluate BG, length of stay, and infectious complications.
Results: The baseline cohort included 64 BMT admissions,
while there were 70 BMT admissions in the intervention
cohort and 102 oncology admissions not part of the inter-
vention. 14% of patients in each of the three admission
groups had a history of diabetes. 30% of all patients on BMT
were discharged on steroids, compared to 10% on oncology.
On admissions when ﬁnger stick evaluation of BG was
initiated (36% in the BMT intervention cohort, 25% in the
BMT baseline corhort, (P ¼ 0.25), more patients received
short acting insulin as per the algorithm (21% vs 6%, P ¼
0.016), but there was no difference in the number transi-
tioned to long acting insulin. In the intervention cohort, the
proportion of time spent in the BG range of 71-199 increased,
with less time spent with a BG < 70 or > 200 (Figure 1, P <
0.0001). Fewer BMT patients were hyperglycemic within 48
hours of a documented infection in the intervention group
compared to the baseline cohort, but the overall rate of
infection among the three groups was low. Within each
cohort on BMT, 6 admissions had a discharge BG>200, and 3
were discharged on new anti-hyperglycemic medications.
Conclusions: We were able to demonstrate the feasibility of
implementing a program to control and track blood glucose.
Not only were we able to limit hypoglycemic episodes, there
was a lower rate during the intervention compared to baseline.
The results of this retrospective study will allow the design of
larger trials to determinewhether BG control has an impact on
length of stay, infectious complications, and mortality.307
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